This Story is Archived
Broad T-Cell Immunity Against HIV Generated in Prime-Boost Vaccine Phase 1 Trial »
Posted by: stephend 2 years agoVical Incorporated (Nasdaq: VICL) announced today that a "prime-boost" vaccine regimen tested in 40 HIV-uninfected subjects in a National Institutes of Health (NIH) sponsored Phase 1 clinical trial was safe and well-tolerated, and was highly effective in inducing T-cell immune responses with multiple functions that may be important for controlling
Read Full Story at bio.com »
This Story is Archived and Commenting is Closed
Comments: 0
All 0 comments are shown.
